Disc Medicine reports positive data from clinical programs at EHA

Disc Medicine (IRON) presented positive clinical data across its hematology pipeline at the EHA 2024 meeting, highlighting sustained efficacy and safety for bitopertin in EPP from the HELIOS extension study, with an NDA filing planned for the second half of 2025. Additionally, Phase 1b data for DISC-0974 in myelofibrosis anemia showed durable responses, and DISC-3405 demonstrated significant reductions in serum iron levels, leading to the initiation of a Phase 2 trial in polycythemia vera with results expected in 2026. The company's strong cash position supports continued clinical development.

Analysis

Disc Medicine, Inc. (NASDAQ:IRON) presented compelling clinical data at the European Hematology Association (EHA) 2025 annual meeting, reinforcing the potential of its hematologic disease pipeline. Long-term data from the HELIOS open-label extension study for bitopertin in erythropoietic protoporphyria (EPP) demonstrated sustained reductions in protoporphyrin IX levels, notable improvements in quality of life, and favorable liver biomarkers over up to two years of treatment. This supports the company's plan to submit a New Drug Application for bitopertin in the second half of 2025, while the confirmatory APOLLO trial continues. For DISC-0974 in myelofibrosis anemia, longer-term Phase 1b data revealed durable responses, with 50% of non-transfusion dependent patients achieving a sustained hemoglobin increase of at least 1.5 g/dL and 80% of low transfusion burden patients achieving transfusion independence over 16 weeks; initial data from the ongoing Phase 2 RALLY-MF trial are anticipated in H2 2025. Furthermore, DISC-3405 showed promise in a Phase 1 healthy volunteer study by producing sustained reductions in serum iron levels and meaningful hematologic parameter changes, prompting a Phase 2 trial in polycythemia vera with results expected in 2026. An iron pulse study for DISC-3405 also indicated significant inhibition of dietary iron uptake by 94% at day 2 and 68% at day 15 post-treatment. Financially, Disc Medicine, with a $1.76 billion market cap and a "GOOD" financial health rating, appears robust, evidenced by a strong current ratio of 37.65 and a balance sheet holding more cash than debt, positioning it well to fund these advancing programs.

Key Decisions for Investors

• Investors should recognize the significant clinical validation across Disc Medicine's pipeline, particularly the sustained efficacy for bitopertin in EPP, which is progressing towards an NDA submission in H2 2025.
• The company's strong financial health, highlighted by a current ratio of 37.65 and a net cash position, substantially de-risks the funding runway for ongoing pivotal trials and upcoming regulatory milestones.
• Key catalysts to monitor include the bitopertin NDA filing, initial Phase 2 data for DISC-0974 in myelofibrosis anemia during H2 2025, and Phase 2 results for DISC-3405 in polycythemia vera expected in 2026, all of which could serve as significant value inflection points.